Chi Sheng Pharma & Biotech Past Earnings Performance
Past criteria checks 2/6
Chi Sheng Pharma & Biotech has been growing earnings at an average annual rate of 22.7%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 2.8% per year. Chi Sheng Pharma & Biotech's return on equity is 5.6%, and it has net margins of 6.5%.
Key information
22.7%
Earnings growth rate
22.7%
EPS growth rate
Pharmaceuticals Industry Growth | 18.5% |
Revenue growth rate | 2.8% |
Return on equity | 5.6% |
Net Margin | 6.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend
Apr 06A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Mar 10Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 01Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield
Jan 05Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Dec 10Revenue & Expenses BreakdownBeta
How Chi Sheng Pharma & Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,061 | 69 | 260 | 22 |
30 Sep 23 | 1,090 | 116 | 265 | 23 |
30 Jun 23 | 1,115 | 151 | 262 | 22 |
31 Mar 23 | 1,130 | 164 | 254 | 20 |
31 Dec 22 | 1,143 | 179 | 249 | 20 |
30 Sep 22 | 1,105 | 186 | 227 | 18 |
30 Jun 22 | 1,085 | 150 | 219 | 19 |
31 Mar 22 | 1,059 | 129 | 219 | 19 |
31 Dec 21 | 1,022 | 108 | 219 | 19 |
30 Sep 21 | 1,003 | 56 | 233 | 19 |
30 Jun 21 | 971 | 41 | 235 | 19 |
31 Mar 21 | 953 | 46 | 231 | 19 |
31 Dec 20 | 979 | 59 | 229 | 18 |
30 Sep 20 | 1,005 | 72 | 228 | 19 |
30 Jun 20 | 1,026 | 80 | 227 | 19 |
31 Mar 20 | 1,047 | 85 | 234 | 20 |
31 Dec 19 | 1,023 | 72 | 232 | 21 |
30 Sep 19 | 998 | 57 | 233 | 22 |
30 Jun 19 | 985 | 57 | 233 | 22 |
31 Mar 19 | 964 | 46 | 229 | 22 |
31 Dec 18 | 967 | 42 | 229 | 23 |
30 Sep 18 | 985 | 52 | 227 | 24 |
30 Jun 18 | 1,016 | 60 | 227 | 24 |
31 Mar 18 | 1,032 | 69 | 222 | 23 |
31 Dec 17 | 1,045 | 82 | 219 | 23 |
30 Sep 17 | 1,034 | 91 | 213 | 20 |
30 Jun 17 | 1,012 | 88 | 209 | 19 |
31 Mar 17 | 995 | 85 | 209 | 19 |
31 Dec 16 | 964 | 73 | 207 | 19 |
30 Sep 16 | 946 | 48 | 210 | 25 |
30 Jun 16 | 936 | 46 | 207 | 26 |
31 Mar 16 | 938 | 42 | 203 | 25 |
31 Dec 15 | 932 | 39 | 203 | 26 |
30 Sep 15 | 908 | 40 | 191 | 20 |
30 Jun 15 | 922 | 50 | 187 | 18 |
31 Mar 15 | 925 | 59 | 184 | 19 |
31 Dec 14 | 943 | 73 | 178 | 18 |
30 Sep 14 | 979 | 104 | 177 | 18 |
30 Jun 14 | 974 | 105 | 176 | 17 |
31 Mar 14 | 960 | 106 | 173 | 16 |
31 Dec 13 | 921 | 96 | 171 | 16 |
30 Sep 13 | 890 | 75 | 173 | 17 |
30 Jun 13 | 849 | 62 | 170 | 18 |
Quality Earnings: 4111 has high quality earnings.
Growing Profit Margin: 4111's current net profit margins (6.5%) are lower than last year (15.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4111's earnings have grown significantly by 22.7% per year over the past 5 years.
Accelerating Growth: 4111's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4111 had negative earnings growth (-61.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-15%).
Return on Equity
High ROE: 4111's Return on Equity (5.6%) is considered low.